Welcome to our dedicated page for COLGATE PALMOLIVE CO SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Colgate-Palmolive Company filings document a global consumer-products issuer with NYSE-listed common stock and registered debt securities. The company's 8-K reports cover earnings releases, the Strategic Growth and Productivity Program, reportable operating segment realignments, senior-note activity, debt-listing changes and governance events such as director elections and officer succession.
Proxy materials describe board elections, executive compensation, shareholder voting matters and strategic priorities tied to growth, efficiency and cash flow. The filings also identify registered securities, including common stock and multiple note series, and provide formal records for shareholder meetings, compensation arrangements and changes affecting listed note classes.
Colgate-Palmolive common stock holder plans Rule 144 sale of 15,000 shares of common stock through Merrill Lynch on the NYSE, with an aggregate market value of 1,467,111.44. The issuer reports 806,064,942 common shares outstanding.
The 15,000 shares were acquired on 02/12/2026 via an exercise of employee stock options in a broker-assisted cashless exercise, with payment also on 02/12/2026. The filing also lists a prior sale of 35,000 common shares on 02/11/2026 by Panagiotis Tsourapas for gross proceeds of 3,311,325.24.
Colgate-Palmolive Chief Growth Officer Hazlin John exercised stock options for 20,989 shares of common stock at $76.41 per share on February 10, 2026, then sold 20,989 shares at a weighted average price of $94.2499 per share. A portion of the sale proceeds was delivered to the company to pay the option exercise price and related tax withholding. After these transactions, John directly owned 17,645 shares and indirectly held 5,452 shares through the issuer's 401(k) plan trustee.
A shareholder associated with Colgate-Palmolive Company has filed a notice to sell 35,000 shares of common stock on the NYSE through Merrill Lynch. The planned sale has an aggregate market value of $3,311,325.26.
The shares were acquired on 02/11/2026 through the exercise of employee stock options via a broker-assisted cashless exercise, with payment also dated 02/11/2026. Colgate-Palmolive had 806,064,942 shares outstanding of common stock at the time referenced.
Colgate-Palmolive executive Malcolm Gregory reported an employee stock option exercise and related share sale. On February 6, 2026, he exercised options for 12,747 shares of common stock at $76.41 per share under the company’s incentive compensation plan.
That same day, he sold 12,747 shares of Colgate-Palmolive common stock in market transactions at a weighted average price of $94.9103 per share, with individual trades ranging from $94.79 to $95.01. After these transactions, he directly owned 11,879 shares and held an additional 8,554 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive common stock holder plans to sell shares under Rule 144. A holder has filed a notice to sell 20,989 shares of Colgate-Palmolive common stock through Merrill Lynch on or about 02/10/2026, with an indicated aggregate market value of $1,978,210.97 on the NYSE.
The shares were acquired on 02/10/2026 from Colgate-Palmolive via an employee stock option exercise structured as a broker-assisted cashless exercise. Colgate-Palmolive had 806,064,942 shares outstanding at the time referenced, providing context for the relative size of this planned sale.
Colgate-Palmolive Chief Human Resources Officer Sally Massey reported an option exercise and related share sale. On February 5, 2026, she exercised stock options for 15,851 shares of common stock at $76.41 per share, awarded under the company’s incentive compensation plan.
That same day, she sold 15,851 shares of common stock at a weighted average price of $95.0279, with part of the proceeds used to pay the option exercise price and related tax withholding. After these transactions, she directly owned 13,751 shares of Colgate-Palmolive common stock and held an additional 8,111 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive’s Chief Financial Officer, Stanley J. Sutula III, exercised stock options and sold shares in a planned transaction. On February 4, 2026, he exercised 97,843 stock options at an exercise price of $81.78 per share under the company’s incentive compensation plan.
That same day, he sold 97,843 shares of common stock at a weighted average price of $94.2662 per share, with a portion of the proceeds delivered to Colgate-Palmolive to cover the option exercise price and related tax withholding. After these transactions, he directly owned 55,310 common shares and indirectly held 328 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive’s Chief Legal Officer and Secretary, Jennifer Daniels, reported an option exercise and share sale. On February 4, 2026, she exercised stock options for 22,000 shares of common stock at $72.29 per share under the company’s incentive plan, increasing her direct holdings to 98,406 shares.
That same day, she sold 22,000 shares of common stock at a weighted average price of $94.3363 per share in multiple transactions, leaving 76,406 shares held directly. A footnote explains that part of the sale proceeds went to Colgate-Palmolive to cover the option exercise price and related tax withholding. She also holds 1,837 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive Chairman, President & CEO Noel R. Wallace reported a sale of common stock. On February 4, 2026, he sold 45,568 shares of Colgate-Palmolive common stock at a weighted average price of $93.9145 per share, in multiple transactions within a stated price range.
After this sale, Wallace directly owned 293,188 common shares. He also reported indirect ownership of 54,281 shares through the issuer's 401(k) plan trustee, 52,000 shares through a spouse trust, and 335 shares through another trust.
Colgate-Palmolive (CL) has a planned Rule 144 stock sale by a shareholder following an option exercise. The holder intends to sell 22,000 shares of Colgate-Palmolive common stock through Merrill Lynch on or around 02/04/2026 on the NYSE, with an aggregate market value of $2,075,398.18.
The shares were acquired the same day by exercising employee stock options via a broker-assisted cashless exercise. Colgate-Palmolive had 806,064,942 common shares outstanding, providing context for the size of this proposed sale.